Web6 dec. 2024 · About Ionis Pharmaceuticals, Inc. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, … WebIonis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market...
Ionis
Web30 aug. 2024 · CARLSBAD, Calif., Aug. 30, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has earned a $40 million milestone payment from Biogen associated with the pricing approval of SPINRAZA ® (nusinersen) in Japan. WebIONIS PHARMACEUTICALS, INC. (IONS) Add to my list Report Summary Quotes News Ratings Calendar Company Financials Consensus Revisions Funds Summary Most relevant All News Analyst Reco. Other languages Press Releases Official Publications Sector news Upcoming event on IONIS PHARMACEUTICALS, INC. 04/17/23 Needham Healthcare … ease their mind
Biogen Exercises Option with Ionis to Develop and Commercialize ...
WebIonis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the following investor conferences: PR Newswire Ionis reports fourth quarter and full … Web21 jun. 2024 · Based on the 35-week interim trial results, the companies will seek regulatory approval for eplontersen and plan to file a new drug application with the US Food and … Web29 mrt. 2024 · This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of Ionis' technologies, IONIS-MAPT Rx and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and … ease the mind